SCHEMBL1720489

SCHEMBL1720489

N#CCc1ccc(Cl)cc1C(N)=O

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.54
ALDH1A1 P00352 2/20 0.54
GLA P06280 1/20 0.54
GAA P10253 1/20 0.54
ADRA1D P25100 4/20 0.46
GABRA1 P14867 3/20 0.43
GABRG2 P18507 3/20 0.43
GABRB3 P28472 3/20 0.43
GABRB2 P47870 2/20 0.43
JAK2 O60674 4/20 0.43
JAK1 P23458 3/20 0.43
TYK2 P29597 3/20 0.43
CYP2A6 P11509 1/20 0.43
ADRA1A P35348 1/20 0.40
ADRA1B P35368 1/20 0.40
EPHX1 P07099 1/20 0.38
NOS2 P35228 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1720423 0.87 KDM4E (0.46) KDM4EALDH1A1GLAGAAADRA1D
SCHEMBL1720342 0.85 ALDH1A1 (0.52) KDM4EALDH1A1GAACYP2A6SMN1; SMN2
SCHEMBL1719977 0.81 MAPK8 (0.39) ALDH1A1SMN1; SMN2
SCHEMBL12505398 0.80 KDM4E (0.58) KDM4EALDH1A1GLAGAAADRA1D
SCHEMBL6802462 0.80 ALDH1A1 (0.46) KDM4EALDH1A1GLAGAAADRA1D
SCHEMBL701597 0.79 KDM4E (0.56) KDM4EALDH1A1GLAGAAADRA1D
SCHEMBL2863807 0.75 BCAT2 (0.46) KDM4EALDH1A1GAAHSD17B10
SCHEMBL1720594 0.75 SMN1; SMN2 (0.52) KDM4EALDH1A1CYP2A6SMN1; SMN2HSD17B10
SCHEMBL6795938 0.74 ADRA1D (0.42) KDM4EALDH1A1GLAGAAADRA1D
SCHEMBL11339655 0.74 CYP2A6 (0.53) ALDH1A1CYP2A6NOS2SMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1566380-B1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2012-01-11 EP disclosed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-05-04 US disclosed
EP-1566380-A1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2005-08-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof PARP1, NQO1, PARP3 KDM4E 3585/4885ALDH1A1 169/4885GLA 601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.